ENGLISH
Abbott Header Logo
Logo Image

It's more than a test.

It's empowering clinicians to make accurate healthcare decisions.

Providing a choice of heart failure tests, offering both BNP and NT-proBNP biomarker assays that can aid in the diagnosis and assessment of severity of heart failure and the Galectin-3 biomarker assay that can aid in assessing the prognosis of patients with chronic heart failure.

For in vitro diagnostic use.

Tennis banner image
Tennis banner image
Tennis banner image

Measuring natriuretic peptide (NP) levels has shown benefit in almost every aspect of heart failure care1–5

Abbott’s range of high-performance tests are designed not to intefere with biotin, enabling the accurate detection of either BNP or NT-proBNP concentrations. The results, when used in conjunction with other clinical information, help define clinical pathways that facilitate accurate diagnoses and optimize patient care.1-4, 6-9

Recognizing the complexities of heart failure diagnosis and prognosis

Heart failure may have a complex presentation and can be difficult to diagnose due to non-specific symptoms, such as dyspnea.11,12 Misdiagnosis can lead to morbidity and in-hospital mortality and re-admission rates are high.13,14

Hospitalization for heart failure is linked to poor prognosis, with up to 30% of patients dying within the following year. Hospitalization is also a major driver of healthcare costs.10

Optimizing diagnosis to tackle the global burden of Heart failure 

Heart failure results in significant clinical, social and economic burdens.15,16
The accurate assessment of patients is vital for optimizing resources and improving outcomes.

64.3 million people worldwide are living with heart failure17

>1 million hospitalizations annually in both US and Europe18

1 in 5 patients are re-hospitalized within 30 days.17

 

44% of patients are re-hospitalized within 60 days19


Click each tab for product information 1-4, 6,7*†

The Alere NT-proBNP assays for Alinity i and ARCHITECT are to be used as an aid in the diagnosis of individuals suspected of having congestive heart failure and detection of mild forms of cardiac dysfunction. The tests also aid in the assessment of heart failure severity in patients diagnosed with congestive heart failure.

The Alere NT-proBNP for Alinity i and ARCHITECT assays are further indicated for the risk stratification of patients with acute coronary syndrome and congestive heart failure, and can also be used for the monitoring the treatment in patients with left ventricular dysfunction.

The Alinity i and ARCHITECT BNP assays are to be used as an aid in the diagnosis and assessment of severity of heart failure.

The Alinity i and ARCHITECT Galectin-3 assays can be used in conjunction with clinical evaluation as an aid in assessing the prognosis of patients with chronic heart failure.

* Results are to be used in conjunction with other clinical information and findings.

† Available on both Alinity i and ARCHITECT.

Find Out More

Our physician resource provides further information on how the BNP and NT-proBNP assays from Abbott, aid in the diagnosis and assessment of heart failure.

Download the physician resource
Experimenting image
Experimenting image
Experimenting image

An accurate reflection of heart failure severity

Both BNP and NT-proBNP levels have been shown to accurately reflect heart failure severity, correlating well with the New York Heart Association (NYHA) classification.14

The following table compares BNP to NT-proBNP on a variety of key attributes.
Each assay offers its own distinct advantages:

BNP

NT-proBNP

Cut-offs1-4

One cut-off for diagnosis ( > 100 pg/mL) 

Multiple age-related cut-offs for diagnosis

Grey Zone20

Narrow

Wider

Renal Dysfunction20

BNP less affected by renal dysfunction

NT-proBNP more affected by renal dysfunction

Sample Stability1-4

4 hours (room temperature); 24 hours (2–8°C)

3 days (room temperature); 6 days (2–8°C)

Sample Type1-4

EDTA plasma

Plasma/serum

BNP and NT-proBNP clinical decision points20

 

 

For BNP, all manufacturers currently suggest a single-decision cut off of 100 pg/mL.20

For NT-proBNP, multiple age-related cut offs are used:3,4

125 pg/mL < 75 yrs
450 pg/mL ≥ 75 yrs

 

ICON study recommends several cut-offs for NT-proBNP:21

Rule-out:
300 pg/mL

Rule-in:
450 pg/mL <50 yrs
900 pg/mL 50–75 yrs
1800 pg/mL >75 yrs

Adapted from McCullough et al, 2009.

 

* Age over 50 years or renal dysfunction.
† Other non-heart failure conditions may be contributing to elevation.

 

For more information on the difference between BNP and NT-proBNP, please refer to the Physician Brochure.

Explore

Understand the Value of Troponin

Explore how STAT High Sensitive Troponin-I may enable easier management of patients with suspected AMI.

Learn about Troponin

Cardiac Assays

Instill confidence in your cardiac care decision making with our comprehensive cardiac assay menu.

View Cardiac Solutions

Visit the Knowledge Center

Find the latest information in laboratory science, therapeutic areas and Abbott innovation.

Visit the knowledge center
References
  1. ARCHITECT BNP reagent package insert. 616-001_R02. August 2018.
  2. Alinity i BNP reagent package insert. 704-328_R04. March 2018.
  3. ARCHITECT Alere NT-proBNP package insert. ABBL458/R05. April 2020.
  4. Alinity i Alere NT-proBNP package insert. ABBL535R04. June 2020.
  5. Pandit K, Mukhopadhyay P, Ghosh S, et al. Natriuretic peptides: Diagnostic and therapeutic use. Indian J Endocrinol Metab. 2011;15(4):345–53.
  6. Alinity i Galectin-3 Reagent Kit package insert. 708-325_R01. December 2018.
  7. ARCHITECT Galectin-3 Reagent package insert. 609-032 8/15/R05. September 2015.
  8. McCullough PA, Olobatoke A, Vanhecke TE. Galectin-3: a novel blood test for the evaluation and management of patients with heart failure. Rev Cardiovasc Med. 2011;12(4):200-10.
  9. de Boer RA, Yu L, van Veldhuisen DJ. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep. 2010;7(1):1-8. Erratum in: Curr Heart Fail Rep. 2012;9(3):163.
  10. Bradley J, Schelbert EB, Bonnett LJ, et al. Predicting hospitalisation for heart failure and death in patients with, or at risk of, heart failure before first hospitalisation: a retrospective model development and external validation study. Lancet Digit Health. 2022;4(6):e445-e454.
  11. Lin DC, Diamandis EP, Januzzi JL, et al. Natriuretic peptides in heart failure. Clin Chem. 2014;60(8):1040-1046.
  12. Ponikowski P, Voors AA, Anker SD, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-2200.
  13. Mueller C, Laule-Kilian K, Schindler C, et al. Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. Arch Intern Med. 2006;166(10):1081-1087. 

 

  1. McCullough P, Omland T, Maisel A. B-Type Natriuretic Peptides: A Diagnostic Breakthrough for Clinicians. Rev Cardiovasc Med. 2003:4(2):72–80.
  2. Savarese G, Becher PM, Lund LH, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023 Jan 118(17):3272-3287.
  3. Lippi G, Giuseppe L, Sanchis-Gomar F. Global epidemiology and future trends of heart failure. AME Medical Journal. 2020:15.
  4. Groenewegen A, Rutten FH, Mosterd A, et al. Epidemiology of heart failure. Eur J Heart Fail. 2020;22(8):1342-1356.
  5. Lahoz R, Fagan A, McSharry M, et al. Recurrent heart failure hospitalizations are associated with increased cardiovascular mortality in patients with heart failure in Clinical Practice Research Datalink. ESC Heart Fail. 2020 (4):1688-1699.
  6.  O'Connor CM, Miller AB, Blair JE, et al. Efficacy of Vasopressin Antagonism in heart Failure Outcome Study with Tolvaptan (EVEREST) investigators. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. Am Heart J. 2010;159(5):841-849.e1. Erratum in: Am Heart J. 2012:163(5):900.
  7. McCullough PA, Neyou A. Comprehensive Review of the Relative Clinical Utility of B-Type Natriuretic Peptide and N-Terminal Pro-B-Type Natriuretic Peptide Assays in Cardiovascular Disease. Open HF J. 2009;2:6-17.
  8. Januzzi JL Jr, Chen-Tournoux AA, Christenson RH, et al. ICON-RELOADED Investigators. N-Terminal Pro-B-Type Natriuretic Peptide in the Emergency Department: The ICON-RELOADED Study. J Am Coll Cardiol. 2018;71(11):1191-1200.

 

Logo Image

©2024 Abbott. All rights reserved.

All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. Any photos displayed are for illustrative purposes only. Any person depicted in such photos may be a model. Please read the Legal Notice for further details.

All ARCHITECT analyzers, Alinity hq, CELL-DYN Ruby and CELL-DYN Emerald 22 AL instruments are Class I laser products. ACCELERATOR APS and ACCELERATOR a3600 are Class II laser products.

The Alinity, ARCHITECT and CELL-DYN systems are intended for performing in vitro diagnostic assays on samples of human origin. Read the instructions in the system manuals and labeling and/or reagent instructions carefully.

This website contains general information about our products sold worldwide. Product availability varies by country. For product availability in your country, please contact your local representative from Abbott. Certain products described or certain features of some products described on this global page might not be commercially available in your country. Content is intended for healthcare professionals only.

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.

Do you wish to continue and exit this website?

You are about to enter an Abbott country or region specific website.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.

Do you wish to continue and enter this website?

NO